Infectious Disease · Medical Literature
[Correspondence] 25 years of antibiotics: from desperate access to precision safety
Abstract
As The Lancet Infectious Diseases approaches its 25-year anniversary, your Editorial1—and its call for stories of success, hope, and inspiration—resonated strongly with our team. In our intensive care unit (ICU), one such story began with an uncomfortable series of questions at the bedside: “Will tigecycline work?”, “Can we keep this patient safe while it works?”, and “Do we have any other options?”
Clinical relevance
How has the clinical approach to tigecycline use in the ICU evolved over 25 years — from desperate empirical access to precision-guided safety monitoring — and what lessons does this trajectory offer for antibiotic stewardship? __SNAPSHOT__ {"studyDesign":"Expert correspondence / narrative commentary (no original empirical data; no control group; no statistical analysis)","setting":"Intensive care unit (ICU); country and specific institution not reported in the excerpt","sampleSize":"Not applicable — no patient cohort studied","population":"Critically ill ICU patients requiring last-resort antibiotic therapy; specific inclusion criteria not reported","intervention":"Tigecycline — a glycylcycline broad-spectrum intravenous antibiotic used in multidrug-resistant (MDR) infections","comparator":"Not applicable — single-arm experiential narrative","primaryOutcome":"Not formally defined; the commentary addresses three clinician-framed questions: efficacy of tigecycline, patient safety during therapy, and availability of alternative options","followUp":"Not reported","fundingSource":"Not reported"}
Key findings
This correspondence contains no original quantitative data, effect sizes, p-values, confidence intervals, or patient-level outcomes. It is a reflective narrative framing clinical questions that ICU practitioners have encountered over 25 years of tigecycline use: whether the drug will work ('Will tigecycline work?'), whether it can be administered safely ('Can we keep this patient safe while it works?'), and whether alternatives exist ('Do we have any other options?'). These three questions implicitly reference well-documented concerns about tigecycline: its FDA Boxed Warning noting a 0.6% adjusted risk difference in all-cause mortality compared with comparators (95% CI 0.1–1.2; reported in FDA labeling), its suboptimal pharmacokinetics (high volume of distribution, low plasma concentrations at standard dosing), its bacteriostatic mechanism, its known adverse event profile (nausea >29%, vomiting >19%, pancreatitis, hepatotoxicity), and the progressive narrowing of its guideline-supported indications — including removal as a component of combination therapy in the 2023 IDSA AMR guidance. No new statistics or outcomes are introduced in this piece. All quantitative context above is drawn from regulatory labeling and published meta-analyses, not from this correspondence itself.
Practice implications
This correspondence does not establish new clinical evidence and should not be interpreted as a data-driven practice-change communication. Its value is reflective and educational: it situates the tigecycline experience within a 25-year arc of infectious disease practice, capturing the tension clinicians face when treating MDR ICU infections with agents whose safety signals are real but whose alternatives may be unavailable. The clinical questions posed — efficacy, safety monitoring, and access to alternatives — mirror the current regulatory and guideline landscape: tigecycline carries an FDA Boxed Warning for increased all-cause mortality, has been de-emphasized in IDSA guidance, and is now formally recommended only when alternative treatments are not suitable. Clinicians cannot extrapolate specific practice recommendations from this letter alone. The broader evidence base (meta-analyses, PK/PD studies, guideline updates) must inform actual tigecycline prescribing decisions. This summary is based solely on the abstract/excerpt; the full correspondence was not available for review, which is a critical limitation. __LIMITATIONS__ Not an original research study — no hypothesis testing, no patient data, no control group, no statistical analysis.,Correspondence format: brief, opinion-driven, and subject to editorial brevity constraints that preclude comprehensive evidence synthesis.,No PMID available; full text not accessible at time of review — only the abstract/excerpt was evaluated.,The reflective narrative framework may introduce selection bias in how the 25-year clinical experience is characterized.,No specific patient population, sample size, or outcomes are defined, preventing any assessment of generalizability.,Does not systematically address heteroresistance, PK/PD optimization, therapeutic drug monitoring, or the role of newer agents (e.g., eravacycline, omadacycline, ceftazidime-avibactam) that now offer alternatives in many MDR settings.,Country and institutional context not reported, limiting assessment of local resistance ecology and drug availability. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ This Lancet Infectious Diseases correspondence is a reflective, expert narrative — not an original research study — and generates no new clinical evidence. It articulates three enduring bedside questions about tigecycline (efficacy, safety, and alternatives) that remain clinically relevant given the drug's FDA Boxed Warning for excess mortality, its bacteriostatic limitations, and its progressively narrowed guideline role. Clinicians should consult current IDSA guidance, PK/PD literature, and institutional stewardship programs — not this letter alone — when making tigecycline prescribing decisions in critically ill patients.